Breast cancer. Stage III: Utility of sistemic treatment
Cáncer de mama. Estadio III: Utilidad de los tratamientos sistémicos
Resumen:
In a group of 229 patients with breast cancer, 81 con•sult in stage 111; 32 were in the 111/A step and 49 in the111/B. According to statistical analysis in wich survivalwas correlated with treatment were they local, regionalor sistemic, we can conclude the utility of chemotherapyand hormonotherapy specially in 111/B stage. Thisresults are explained by the metastatic potential thatthis group of patients has showed. This group benefitsof this treatments
En una población de 229 portadores de cáncer mamario,81 consultaron por Estadio 111; en el IIIA lo hicieron32 y 49 en el 111B. Según el estudio estadísticoen el que se correlacionó las sobrevidas de dichos gru•pos en función de los tratamientos, fueran ellos loco•regionales o c:o!stémicos, se desprende la utilidad de laquimio-hormonoterapia en especial en el Estadio 111B.Resultados que se explican por el potencial metastásicomanifiesto en ese grupo de pacientes, los que se be•nefician del alcance de dichos recursos.
1984 | |
mama c´áncer breast cancer |
|
Español | |
Sociedad de Cirugía del Uruguay | |
Revista Cirugía del Uruguay | |
https://revista.scu.org.uy/index.php/cir_urug/article/view/3553 | |
Acceso abierto |
Sumario: | In a group of 229 patients with breast cancer, 81 con•sult in stage 111; 32 were in the 111/A step and 49 in the111/B. According to statistical analysis in wich survivalwas correlated with treatment were they local, regionalor sistemic, we can conclude the utility of chemotherapyand hormonotherapy specially in 111/B stage. Thisresults are explained by the metastatic potential thatthis group of patients has showed. This group benefitsof this treatments |
---|